Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 7—July 2015
Research

Monitoring of Ebola Virus Makona Evolution through Establishment of Advanced Genomic Capability in Liberia

Jeffrey R. Kugelman1, Michael R. Wiley1, Suzanne Mate1, Jason T. Ladner1, Brett Beitzel, Lawrence Fakoli, Fahn Taweh, Karla Prieto, Joseph W. Diclaro, Timothy Minogue, Randal J. Schoepp, Kurt E. Schaecher, James Pettitt, Stacey Bateman, Joseph Fair, Jens H. Kuhn, Lisa Hensley, Daniel J. Park, Pardis C. Sabeti, Mariano Sanchez-Lockhart, Fatorma K. Bolay, Gustavo PalaciosComments to Author , on behalf of US Army Medical Research Institute of Infectious DiseasesNational Institutes of HealthIntegrated Research Facility–Frederick Ebola Response Team 2014–2015
Author affiliations: US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, USA (J.R. Kugelman, M.R. Wiley, S. Mate, J.T. Ladner, B. Beitzel, K. Prieto, T. Minogue, R.J. Schoepp, K.E. Schaecher, S. Bateman, M. Sanchez-Lockhart, G. Palacios); Liberian Institute for Biomedical Research, Charlesville, Liberia (L. Fakoli, F. Taweh, F.K. Bolay); Naval Medical Research Unit 3, Cairo, Egypt (J.W. Diclaro); Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick (J. Pettitt, J.H. Kuhn, L. Hensley); Foundation Merieux, Washington, DC, USA (J. Fair); Broad Institute, Cambridge, Massachusetts, USA (D.J. Park, P.C. Sabeti); Center for Systems Biology, Harvard University, Cambridge (P.C. Sabeti)

Main Article

Table 3

Mutation analysis of candidate therapeutic drug and diagnostic binding sites for EBOV*

Reference position Type Reference base Called base EBOV-WA, % EBOV-LIB, % Codon Feature name
850 SNP A G 100 100 G:GGA @ 127 → G:GGg NP
852 SNP A G 100 100 K:AAA @ 128 → R:AgA NP
895 SNP A G 100 100 T:ACA @ 142 → T:ACg NP
907 SNP T C 1 0 N:AAT @ 146 → N:AAc NP
919 SNP T C 100 100 F:TTT @ 150 → F:TTc NP
1288 SNP A T 1 0 V:GTA @ 273 → V:GTt NP
1495 SNP A G 100 100 Q:CAA @ 342 → Q:CAg NP
1498 SNP C T 1 4 L:CTC @ 343 → L:CTt NP
1507 SNP T A 100 100 A:GCT @ 346 → A:GCa NP
1552 SNP C T 100 100 R:CGC @ 361 → R:CGt NP
1862 SNP A G 100 100 S:AGC @ 465 → G:gGC NP
6359 SNP T C 100 100 N:AAT @ 107 → N:AAc GP
6909 SNP T A 1 0 W:TGG @ 291 → R:aGG GP
7730 SNP G A 100 100 E:GAG @ 564 → E:GAa GP
7775 SNP A G 100 100 L:CTA @ 579 → L:CTg GP
7778 SNP C A 100 100 R:CGC @ 580 → R:CGa GP
10252 SNP A T 1 4
10253 SNP A G 1 0
12694 SNP T A 100 100 I:ATT @ 371 → I:ATa L
12886 SNP A C 2 0 L:CTA @ 435 → L:CTc L
12952 SNP A G 100 100 L:CTA @ 457 → L:CTg L
13267 SNP C T 100 100 T:ACC @ 562 → T:ACt L
13607 SNP G A 1 4 V:GTC @ 676 → I:aTC L
13624 SNP T G 1 0 N:AAT @ 681 → K:AAg L
13630 SNP A G 100 100 P:CCA @ 683 → P:CCg L

*EBOV, Ebola virus; GP; glycoprotein, ; L, RNA-dependent RNA polymerase; LIB, Liberia; NP; nucleoprotein; SNP, single-nucleotide polymorphism; WA, Western Africa.

Main Article

1These authors contributed equally to this article.

Page created: June 12, 2015
Page updated: June 12, 2015
Page reviewed: June 12, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external